|
|
|
|
|
by suddenseizure
2582 days ago
|
|
I've been following this field with great interest since my wife was diagnosed with brain cancer. It seems many types of cancer can evolve resistance to treatment with a single type of immunotherapy. Similar to how HIV quickly evolved resistance to treatment by one ARV (antiretroviral). But HIV can be kept in check by a cocktail of 3 ARVs simultaneously. And there's some recent research from Mass General where they managed to eradicate brain tumors in mice using 3 different immunotherapies simultaneously: https://advances.massgeneral.org/neuro/journal.aspx?id=1263 > Dr. Curry's group describes "a likely oversimplified, but reasonable" summary of the mechanism of the triple therapy: GVAX expands the number and diversity of activated tumor-specific T cells and increases the number of intratumor CD8+ T cells, while PD-1 inhibition further invigorates the effects of those mobilized cells. Meanwhile, agonist anti-OX40 continues to skew systemic and tumor microenvironments toward Th1 immunity, suppress regulatory T cells and prevent T cell exhaustion. Hopefully this is a way forward for treating humans too! |
|
There are cases of adaptive resistance to immune-based therapies. These are less common, although they do arise. However, it is still the same kind of game - tumors use the same tricks to hide from an immune response ignited by an immunotherapy as they do from an immune response without immunotherapy.